Unibest

Pharmaceutical intermediates

Nintedanib Esylate Intermediates

5 pharmaceutical intermediates for Nintedanib Esylate. Indication: Systemic sclerosis-related interstitial lung disease; Idiopathic pulmonary fibrosis; Non-small cell lung cancer.

提交项目All intermediates

About Nintedanib Esylate

Originator
Boehringer Ingelheim
Indication
Systemic sclerosis-related interstitial lung disease; Idiopathic pulmonary fibrosis; Non-small cell lung cancer
Approved Date
10/15/2014
DS/DP
10/01/2025

Available intermediates

5 intermediates currently listed for Nintedanib Esylate. Request specifications, documentation or a quotation for any item below.

Nintedanib Esylate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-Chloro-N-methyl-N-(4-nitrophenyl)acetamide2653-16-9//
Trimethyl orthobenzoate707-07-3//
N-(4-Aminophenyl)-N-methyl-2-(4-methylpiperazin -1-yl)acetamide262368-30-9//
Methyl 2-oxoindole-6-carboxylate14192-26-8//
(3E)-2,3-Dihydro-3-(methoxyphenylmethylene) -2-oxo-1H-indole-6- carboxylic acid methyl ester1168150-46-6//

Other programs under N

Nafamostat mesylateNebivolol HydrochlorideNemorexantNeratinib/ PyrotinibNilotinibNiraparib

Building toward Nintedanib Esylate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →